A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards
Open Access
- 1 November 2003
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 1 (11), 2283-2289
- https://doi.org/10.1046/j.1538-7836.2003.00481.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Coagulation and Chromogenic Assays of Factor VIII Activity: General Aspects, Standardization, and RecommendationsSeminars in Thrombosis and Hemostasis, 2002
- Assaying the Circulating Factor VIII Activity in Hemophilia A Patients Treated with Recombinant Factor VIII ProductsSeminars in Thrombosis and Hemostasis, 2002
- The Use of Recombinant Factor VIII Products in Previously Treated Patients with Hemophilia A: Pharmacokinetics, Efficacy, Safety, and Inhibitor DevelopmentSeminars in Thrombosis and Hemostasis, 2002
- B-domain deleted recombinant factor VIII formulation and stabilitySeminars in Hematology, 2001
- The manufacturing process for B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- Influence of phospholipids on the assessment of factor VIII activityHaemophilia, 1998
- In vivo recovery with products of very high purity — assay discrepanciesHaemophilia, 1998
- Discrepancies in potency assessment of recombinant FVIII concentratesHaemophilia, 1998
- PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curvesComputer Methods and Programs in Biomedicine, 1992
- Potency of high purity factor VIII concentratesThe Lancet, 1990